Postmenopausal hormone therapy: Cardiovascular risk

Prescrire International

Volumn 12, Issue 64, 2003, Pages 65-69

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; PHYTOESTROGEN; PLACEBO; PRASTERONE; PROGESTERONE DERIVATIVE; TIBOLONE; GESTAGEN;

ADULT; ANAMNESIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; MORTALITY; OUTCOMES RESEARCH; POSTMENOPAUSE; PRESCRIPTION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS; VERTEBRA FRACTURE; ARTICLE; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; ESTROGEN THERAPY; HEALTH SERVICE; RISK FACTOR;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; WOMEN'S HEALTH SERVICES;

EID: 0037390961     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Prescrire Rédaction "estradiol + lévonorgestrel par voie transdermique (Femseptcombi°) - pas assez de sécurité d'emploi dans le traitement substitutif de la ménopause" Rev Prescr 2002 ; 22 (234) : 805-808. [see this issue p. 59]
2. Prescrire Editorial Staff "Intranasal estradiol" Prescr Int 2002; 11 (62): 163-165.
3. Prescrire Rédaction "estradiol + noréthistérone (Activelle°) - nouveau dosage: simplement un demi Kliogest°" Rev Prescr 2002; 22 (225): 105.
4. Prescrire Rédaction "estradiol + dydrogestérone - pas d'avantage démontré pour la ménopause" Rev Prescr 1999; 19 (198): 566-569.
5. Prescrire Rédaction "estradiol transdermique (Climara°, Femsept°, Dermestril°) - plus de souplesse posologique" Rev Prescr 1999; 19 (194): 259-261.
6. Prescrire Editorial Staff "Fracture prevention in elderly women" Prescr Int 1998; 7 (37): 155-159.
7. Hulley S et al. "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women" JAMA 1998; 280 (7): 605-613.
8. Prescrire Rédaction "Traitement hormonal de la ménopause et risque cardiovasculaire" Rev Prescr 1999; 19 (191): 57-58.
9. Women's health initiative investigators "Risks and benefits of estrogen plus progestin in healthy postmenopausal women, Principal results from the Women's health initiative randomized controlled trial" JAMA 2002; 288 (3): 321-333.
10. Grady D et al. "Cardiovascular disease outcomes during 6.8 years of hormonal therapy - Heart and Estrogen /Progestin replacement study follow-up (HERS II)" JAMA 2002; 288 (I): 49-57.
11. Hulley S et al. "Noncardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/Progestin replacement study follow-up (HERS II)" JAMA 2002; 288 (1): 58-66.
12. Nelson HD et al. "Postmenopausal hormone replacement therapy - Scientific review" JAMA 2002; 288 (7): 872-881.
13. Grodstein F et al. "A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease" Ann Intern Med 2000; 133 (12): 933-941.
14. Grodstein F et al. "Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective observational study" Ann Intern Med 2001; 135 (1): 1-8.
15. Heckbert SR et al. "Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy" Arch Intern Med 2001; 161: 1709-1713.
16. Alexander KP et al. "Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up" J Am Coll Cardiol 2001; 38 (1): 1-7.
17. Humphrey LL et al. "Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease" Ann Intern Med 2002; 137 (4): 273-284.
18. Rossouw JE "Early risk of cardiovascular events after commencing hormone replacement therapy" Curr Opin Lipidol 2001; 12: 371-375.
19. Simon JA et al. "Postmenopausal hormone therapy and risk of stroke. The heart and estrogen-progestin replacement study (HERS)" Circulation 2001; 103: 638-642.
20. Paganini-Hill A et al. "Postmenopausal oestrogen treatment and stroke: a prospective study" BMJ 1988; 297: 519-522.
21. Finucane FF et al. "Decreased risk of stroke among postmenopausal hormone users: results from a national cohort" Arch Intern Med 1993; 153: 73-79.
22. Wilson PW et al. "Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham study" N Engl J Med 1985; 313 (17): 1038-1043.
23. Lemaitre RN et al. "Hormone replacement therapy and associated risk of stroke in postmenopausal women" Arch Intern Med 2002; 162: 1954-1960.
24. Stampfer MJ et al. "Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study" N Engl J Med 1991; 325 (11): 756-762.
25. Tønnes Pedersen A et al. "Hormone replacement therapy and risk of non-fatal stroke" Lancet 1997; 350: 1277-1283.
26. Viscoli CM et al. "A clinical trial of estrogen-replacement therapy after ischemic stroke" N Engl J Med 2001; 345 (17): 1243 -1249.
27. Grady D et al. "Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study" Ann Intern Med 2000; 132 (9): 689-696.
28. Douketis JD et al. "A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy" Arch Intern Med 1997; 157: 1522-1530.
29. Miller J et al. "Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US preventive task force" Ann Intern Med 2002; 136 (9): 680-690.
30. Prescrire Rédaction "Reconnaître les facteurs de risque d'embolie pulmonaire" Rev Prescr 2002; 22 (229): 441-443.
31. Palin SL et al. "HRT in women with diabetes - review of the effects on glucose and lipid metabolism" Diabetes Res Clin Pract 2001; 54: 67-77.
32. Ferrara A et al. "Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes" Diabetes Care 2001; 24 (7): 1144-1150.
33. Aguilar-Salinas CA et al. "The healthy women bias and hormone replacement therapy in women with type 2 diabetes" (letters) Diabetes Care 2002; 25 (1): 246.
34. Ferrara A et al. "Hormone replacement therapy and glycemic control: evidence from observational studies and randomized clinical trials" (letters) Diabetes Care 2002; 25 (1): 246-247.
35. Crespo CJ et al. "Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the third national health and nutrition examination survey (NHANES III)" Diabetes care 2002; 25 (10): 1675-1680.
36. Manning PJ et al. "The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes. A randomized controlled trial" Arch Intern Med 2001; 161: 1772-1776.
37. Glazier MG and Bowman MA "A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy" Arch Intern Med 2001; 161: 1161-1172.
38. "Ménopause". In: Bruneton J "Phytothérapie - Les données de l'évaluation" Éditions Tec & Doc et Éditions médicales internationales, Paris-Cachan 2002: 173-189.
39. Prescrire Editorial Staff "DHEA" Prescr Int 2002; 11 (60): 118-123.
40. Prescrire Editorial Staff "Tibolone" Prescr Int 2002; 11 (59): 79-82.
41. The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risks factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial" JAMA 1995; 273 (3): 199-208 + 274 (21): 1676.
42. "MRC stops study of long term use of HRT" 23 October 2002. Website http://www.mrc.ac.uk, consulted on 31 October 2002.
43. Khan MA et al. "Oestrogen and women's heart disease: ESPRIT-UK" Q J Med 2000; 93: 699-700.